Table 2. Polymorphisms included within the meta-analysis and their association with CRC risk.

Pathway	Gene	rs number	Number of studies	Cases/controls	Wt allele	Minor allele	MAF	Pooled odds ratio	95% CI	I2
Base excision repair	APE1	rs1130409	5	4,606/5,000	G	G	0.3756	1.15	1.06–1.24	36.38
	MUTYH	rs3219489	3	5,230/2,756	G	G	0.3135	1.14	0.82–1.58	88.23
	OGG1	rs1052133	13	9,682/1,2938	C	G	0.3021	1.05	0.98–1.11	0.00
	PARP1	rs1136410	3	2,132/4,320	T	G	0.1969	1.16	1.04–1.30	15.01
	XRCC1	rs1799782	11	6,190/10,454	C	A	0.1238	1.30	0.96–1.75	86.98
		rs25487	13	7,981/12,226	G	T	0.2604	1.08	0.92–1.26	80.55
		rs25489	3	2,402/3,000	G	T	0.0671	1.03	0.83–1.27	0.00
Homologous recombination repair	RAD18	rs373572	2	2,074/2,298	A	C	0.3524	1.32	1.16–1.49	0.00
	RAD51	rs1801320	5	1,706/1,240	G	C	0.1432	0.83	0.50–1.38	85.96
	XRCC3	rs861539	8	3,850/4,566	C	A	0.2169	1.15	0.85–1.55	82.90
Mismatch repair	MLH1	rs1799977	4	8,252/8,802	A	G	0.1296	1.15	0.96–1.37	82.88
	MSH2	rs2303425	2	4,598/5,602	T	C	0.1008	1.06	0.94–1.19	0.00
	MSH6	rs1042821	3	6,952/8,174	C	A	0.2009	0.98	0.80–1.20	80.04
Nucleotide excision repair	ERCC1	rs11615	4	1,890/1,650	C	A	0.3311	1.03	0.90–1.18	11.22
	ERCC5	rs17655	6	7,912/8,772	C	C	0.3614	1.12	1.06–1.20	0.04
	TP53	rs1042522	12	8,164/10,176	C	G	0.4571	1.18	0.97–1.45	89.23
	XPC	rs2228000	3	3,680/5,212	C	A	0.2330	1.06	0.85–1.32	80.80
		rs2228001	7	6,584/8,930	A	G	0.3153	1.08	1.01–1.15	49.46
	XPD	rs13181	10	4,932/6,210	G	G	0.2366	1.21	0.95–1.54	85.46
		rs1799793	3	1,520/2,244	G	T	0.1954	1.13	0.87–1.45	62.01
Direct reversal repair	MGMT	rs12917	3	1,528/3,332	C	T	0.1484	0.81	0.68–0.98	0.00
		rs2308321	3	1,664/7,016	A	G	0.0513	0.99	0.82–1.19	0.00

CI, confidence interval; CRC, colorectal cancer; MAF, minor allele frequency; Wt, wild type.

Significant results are in bold.